Background: Autoimmune thyroid disease and thyroid dysfunction are common in adults receiving interferon (IFN)-based treatment for chronic hepatitis C (CHC). Few data are available in children with CHC. This study is aimed to evaluate the appearance and timing of thyroid dysfunction and antithyroid autoimmunity in children with CHC treated with pegylated IFN-α-2b and ribavirin (RBV). Methods: Sixty-one otherwise healthy children with CHC, 3-17 years of age, infected perinatally and treatment naïve, receiving therapy with pegylated IFN-α-2b and RBV and 183 age-and sex-matched controls were included in a multicenter, prospective, case-control study. Thyroid-stimulating hormone, free thyroxine, antithyroglobulin antibodies and antithyroid peroxidase antibodies were assessed before, during and 24 weeks after the end of treatment. Results: From baseline to the end of treatment, subclinical hypothyroidism and autoimmune thyroiditis were diagnosed in 17 of 61 (27.94%) and in 4 of 61 (6.6%) of the children treated, respectively, and in 5 of 183 (2.7%) and in none of the controls (P < 0.0001, relative risk: 10.2, 95% confidence interval: 3.9-26.5; P = 0.03, relative risk: 26.8, 95% confidence interval: 1.5-489.1, respectively). Twenty-four weeks after the end of treatment, subclinical hypothyroidism persisted in only 4 of 61 (6.6%). Autoimmune thyroiditis persisted in 3 of 4 (75%) of the cases. Conclusions: Subclinical hypothyroidism is common in children with CHC receiving treatment with pegylated IFN-α-2b and RBV, but in most cases is transient. Autoimmune thyroiditis, which is less common, generally persists after treatment completion. Thyroid function should be carefully monitored in patients presenting with antithyroid autoantibodies and thyroid dysfunction during and after pegylated IFN-α-based treatment.
I nterferon (IFN)-α is a cytokine belonging to type I IFNs produced in vivo by the innate immune system after infections and recognition of pathogens.
1 IFN-α and its pegylated form (peg-IFNα) has been used for treatment of patients with cancer and chronic viral infections. 1 IFN-α-based treatments, despite their well-known beneficial therapeutic effects, have been associated with many adverse events and, among these, with the possible development of autoimmune phenomena. 1 The combination of peg-IFNα and ribavirin (RBV) has been for a long time the standard of care for treatment of adults with chronic hepatitis C (CHC) and is still the only available therapeutic option for children. 2 Peg-IFNα and RBV lead to the resolution of the infection in 89% of children with hepatitis C virus (HCV) genotype 2 or 3 infection and 52% of those with genotypes 1 and 4. 3 The appearance of autoantibodies and new onset of autoimmune diseases have been described in adults 4 and children 5 during and after IFN-α-based treatment. Autoimmune thyroid disease and thyroid dysfunction were described in 20%-40% and 11%-15%, respectively, of the adults with CHC receiving IFN. 6 Two more recently published studies, based on large cohorts of patients, demonstrate that adults with CHC treated with peg-IFNα and RBV present a high incidence of thyroid disease during treatment (35% 7 and 27.7%, 8 respectively) with most of them recovering after completion of therapy. The exact mechanism explaining the relation between IFN-α and thyroid disease is not clear. An immunemediated mechanism has been hypothesized. IFN-α modulates the production of other cytokines, like IFN-γ and IL-6, and creates an imbalance of the immune system which leads to the production of thyroid autoantibodies and to a direct disruptive effect on thyroid function, at the same time. 6, 9 Untreated children with CHC are at risk of both autoimmune and nonautoimmune thyroid disease with subclinical hypothyroidism and autoimmune thyroiditis described, respectively, in 11.1% and 2.8% of treatment-naïve children with chronic infection. 10 Few data are available on the effects of the association of peg-IFNα and RBV on thyroid function and antithyroid autoimmunity in children with CHC. [11] [12] [13] [14] [15] [16] [17] Previous studies provided different figures and were variably biased by the low number of children enrolled, 12, 15, 16 the different sources of infection [11] [12] [13] [14] 16, 17 and treatment histories 11, 12, 15, 16 and the possible presence of comorbidities. 15, 16 Furthermore, thyroid function and autoantibodies were not systematically assessed in every study.
The main aim of the present multicenter, prospective study was to evaluate systematically in a large and homogeneous cohort of treatment-naïve, vertically infected children with CHC treated with peg-IFNα-2b and RBV the appearance and timing of thyroid dysfunction and antithyroid autoimmunity.
December 2015. Children were included if between 3 and 17 years of age, infected perinatally and treatment naïve. Perinatal infection was defined by the detection of HCV RNA in peripheral blood by reverse transcriptase polymerase chain reaction or when anti-HCV antibodies persisted beyond 18 months of age. 19 CHC was defined by the presence of positive anti-HCV antibodies and HCV RNA as detected by reverse transcriptase polymerase chain reaction in at least 2 serum samples taken 6 months apart. 18 The main exclusion criteria included body weight >90 kg, low neutrophils (<1.500/µL) and platelets count (<100.000/µL), low hemoglobin level (<11 g/ dL for female, <12 g/dL for male), high creatinine (>1.5 times the age-appropriate normal value), presence of advanced liver disease, coexisting human immunodeficiency virus or hepatitis B virus infection, diagnosis of autoimmune hepatitis or presence of autoantibodies (liver-kidney microsomal type-1 autoantibody, smooth muscle autoantibody >1:100, antinuclear antibodies >1:160 with homogeneous pattern) and/or of other systemic diseases.
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Controls
HCV-infected children were compared with a control group composed of 183 age-and sex-matched Italian children (94 females: 51.4%, 89 males: 48.6%, median age: 12.6, range: 3.1-16.9 years), admitted to the Meyer Children's University Hospital for minor surgical interventions (eg, adenotonsillectomy, phimosis, dermoid cyst, herniotomy). Part of this group was previously reported. 21 In all controls, HCV infection was excluded at the time of the study.
Treatment
Treatment consisted of peg-IFNα-2b (1.5 µg/kg/wk) onceweekly plus RBV (15 mg/kg/d up to a maximum of 1200 mg/d). Children with genotype 1 or 4 were assigned to 48 weeks of treatment but, if HCV RNA was detectable at week 24, they discontinued treatment and entered the follow-up phase. All children with genotype 2 or 3 were assigned to 24 weeks of treatment. All patients were followed up for 24 weeks after the end of treatment.
Laboratory Investigations
Thyroid-stimulating hormone (TSH), serum free thyroxine (FT4), antithyroglobulin antibodies (anti-TG) and antithyroid peroxidase antibodies (anti-TPO) were assessed on blood samples by commercially available immunometric assays. Results exceeding the upper normal value reported for each test were considered positive. TSH, FT4, anti-TG and anti-TPO were assessed at baseline and during treatment at 4, 8, 12, 18 and 24 weeks for all genotypes and also at 36 and 48 weeks only for genotypes 1 and 4, respectively. TSH, FT4, anti-TG and anti-TPO dosages were performed in all patients at 4, 12 and 24 weeks after completion of treatment.
Definitions
Subclinical hypothyroidism was defined as a TSH level higher than 4 mUI/L, together with normal serum thyroid hormone levels. [22] [23] [24] Overt hypothyroidism was defined as increased TSH and decreased serum thyroid hormone level. 22, 23, 25 Autoimmune thyroiditis was defined by raised anti-TPO and/or anti-TG values, and raised TSH levels and/or typical hypoechogenicity of the thyroid ultrasound (US). 22, 23, 25 The thyroid was considered hypoechogenic when its signal was equal to or below the echogenicity of the surrounding neck muscles. 22, 23, 25 Sustained virologic response (SVR) was defined as undetectable plasma HCV RNA 24 weeks after the end of treatment.
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Statistical Analysis
Data were processed with the IBM SPSS Statistics for Macintosh release 21 statistical package. Results were expressed as median and interquartile range. The Mann-Whitney U test was used to compare continuous variables between 2 groups. Chi-square test and Fisher exact test were performed to test for differences in proportions of categorical variables between 2 groups. Relative risk (RR) with 95% confidence intervals (CIs) was calculated. The level of P < 0.05 was considered significant. 
RESULTS
Sixty
Hypothyroidism and Autoimmune Thyroiditis
From baseline to the end of therapy, 17 children (27.9%) were diagnosed with subclinical hypothyroidism and none with overt hypothyroidism.
Autoimmune thyroiditis was diagnosed in 4 children (6.6%). In this latter group, all the children presented with increased TSH, positive autoantibodies (4 anti-TG and 3 anti-TPO) and 3 had abnormal US. The development of any thyroid disease (subclinical or overt hypothyroidism and autoimmune thyroiditis) did not correlate with age, sex, weight, height and baseline viral load of the patients (Table 1) .
Control Group
Five of 183 (2.7%) subjects had subclinical hypothyroidism with negative antithyroid autoantibodies; no child was diagnosed with overt hypothyroidism or autoimmune thyroiditis. Two (1.1%) subjects showed isolated high titers of antithyroid autoantibodies with normal thyroid function and thyroid US.
HCV-infected Children Versus Controls
Subclinical hypothyroidism was more frequent in HCVinfected children receiving therapy than controls (P < 0.0001, RR: 
Timing of Hypothyroidism and Autoimmune Thyroiditis
At baseline, 2 (3.3%) children had subclinical hypothyroidism while no patient was positive for antithyroid autoantibodies. During treatment, the highest number of patients with thyroid disease was found at week 24 when 10 (16.4%) children presented subclinical hypothyroidism. Twenty-four weeks after the end of treatment, subclinical hypothyroidism persisted in only 4 children.
The TSH trends for each patient with subclinical hypothyroidism, and the TSH median values with ranges have been reported in Supplemental Digital Content 1, http://links.lww.com/ INF/C845. Six (9.8%) children became positive for antithyroid autoantibodies during treatment. Two (3.3%) of them were positive only once at weeks 8 and 18 (1 with anti-TG and 1 with anti-TPO), respectively, and did not show any abnormality in TSH level or thyroid US. The remaining 4 (6.6%) were diagnosed with autoimmune thyroiditis at week 18, which persisted at the last follow-up visit in 3 of them. Of these 4 patients, 1 presented transient autoimmune thyroiditis, as was positive for anti-TG from treatment week 4-8, presented raised TSH from treatment week 8-36 and had a normal thyroid US examination. The remaining 3 became positive both for anti-TG and anti-TPO at weeks 12, 18 and 24, respectively, and presented thyroid hypoechogenicity at US. They were started and are still on treatment with thyroxine replacement therapy. At the end of follow-up, 2 of them (3.3%) were still positive for antithyroid autoantibodies and 1 had negative antibodies.
DISCUSSION
The present study shows that thyroid dysfunction is common in children with CHC treated with peg-IFNα and RBV. In the described cohort, subclinical hypothyroidism and autoimmune thyroiditis were diagnosed in 27.9% and 6.6% of the children treated, respectively. Subclinical hypothyroidism was transient in 13 (76.5%) of 17 cases, respectively. Autoimmune thyroiditis persisted 24 weeks after the end of treatment in 3 (75%) of 4 children.
The present results provide additional knowledge to previous studies evaluating the effects of peg-IFNα and RBV therapy on thyroid function in children ( Table 2 ). The cohort of children enrolled in this study was highly homogeneous being all the children infected vertically, treatment naïve, with no comorbidity and specifically with no preexisting autoimmune disease. Moreover, thyroid function and thyroid autoantibodies were systematically evaluated to detect the exact timing of appearance of TSH abnormalities and anti-TG and/or anti-TPO positivities. Such a strict monitoring of thyroid function and autoantibodies in children with CHC treated with peg-IFNα and RBV was never reported. Previous studies reported prevalence rates of subclinical and overt hypothyroidism ranging between 0%-23% and 0%-5%, respectively. [11] [12] [13] [14] [15] [16] [17] In the present study, subclinical hypothyroidism was diagnosed in 27.9% of patients. This result is higher than previously reported in other studies performed in larger as well as smaller cohorts of children. Only the study of Wirth et al 13 in 2010, based on a large cohort of 107 children, found a similar, slightly lower prevalence (Table 2) . It is possible to speculate that in all the previous studies, the results could have been affected by a less intense monitoring schedule or by the lower number of patients (Table 2) .
Whether the correlation between IFN-based treatment and thyroid dysfunction is a direct consequence of therapy and/or it depends on HCV infection is matter of debate. In a previous study, the prevalence of subclinical hypothyroidism was 11.1% in a cohort of HCV vertically infected, treatment-naïve children. 10 In the present study, the prevalence of subclinical hypothyroidism was more than double (27.9%). These independent observations suggest that both IFN-based treatment and HCV infection play an important role in the development of thyroid dysfunction in children with CHC.
The scenario depicted by the results of the present study allows to define more clearly what could be the approach to patients presenting thyroid dysfunction and/or thyroid autoantibodies during treatment with peg-IFNα and RBV. Children should not be routinely tested for antithyroid autoantibodies, but only if a raised TSH is detected. Those children presenting subclinical hypothyroidism should be reassured that in most instances, this is only a transient event which usually recovers. Thyroid function should be monitored, but progression of the disease is unlikely and replacement therapy with thyroxine generally is not needed. On the other side, children positive for antithyroid autoantibodies and with raised TSH need an accurate endocrine follow-up, including thyroid US scan, because autoimmune thyroiditis usually persists after the completion of treatment.
Peg-IFNα is no longer the standard of care in adults with CHC with the arrival of the new highly effective and safe directacting antiviral agents. 26 Recently, a trial on the use of ledipasvirsofosbuvir in adolescents 12-17 years old with CHC showed promising results with 98% of patients reaching SVR at 12 weeks after treatment. 27 The fixed dose combination of ledipasvir/sofosbuvir and the association of sofosbuvir and RBV have been approved recently by the Food and Drug Administration for the treatment of children 12-17 years old with CHC infected by genotypes 1, 4, 5 or 6 and genotypes 2 and 3, respectively. 28 Hopefully, in the future, these drugs as well as other direct-acting antivirals combinations will be approved also children younger than 12 years. 29 By the time, peg-IFNα and RBV will still be the only treatment available for children with CHC between 3 and 11 years of age. Furthermore, IFN-α is still a mainstay of therapy for chronic hepatitis B in children. [30] [31] [32] Caregivers should be aware of the possible thyroid involvement in children undergoing treatment with peg-IFNα and RBV. A better knowledge about the long-term consequences of thyroid dysfunction and appearance of antithyroid autoantibodies during treatment of CHC in children is mandatory to assure their correct management.
The present study is not free of limitations. The multicenter design did not allow testing blood samples for thyroid function and antithyroid autoantibodies in the same laboratory with only 1 assay. Samples were tested with commercially available kits, which have been verified to be in line with the standard. The definition of subclinical hypothyroidism used in this study, although widely accepted, being based on a single determination of TSH could probably overestimate its real prevalence. 24 The follow-up of the children treated was reported up to 24 weeks after treatment completion and is still ongoing. The possible late onset thyroid dysfunction or late appearance of antithyroid autoantibodies cannot be excluded, and a longer follow-up after treatment is recommended in clinical practice.
This study demonstrates that thyroid dysfunction is common in children treated with peg-IFNα and RBV for CHC. Subclinical hypothyroidism is the most common manifestation, but in most cases is transient. By comparison, autoimmune thyroiditis is less frequent, but generally is a permanent disease. Clinicians who decide to administer peg-IFNα-based treatment to children with CHC should carefully evaluate antithyroid autoantibody appearance and thyroid function during treatment and follow-up to promptly detect any thyroid dysfunction and establish the proper management.
